These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Exanthematous drug eruption due to valsartan. Ozturk G; Turk BG; Senturk B; Turkmen M; Kandiloglu G Cutan Ocul Toxicol; 2012 Dec; 31(4):335-7. PubMed ID: 22257082 [TBL] [Abstract][Full Text] [Related]
29. Valsartan for hypertension. Med Lett Drugs Ther; 1997 Apr; 39(999):43-4. PubMed ID: 9137296 [No Abstract] [Full Text] [Related]
30. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption. Sawada Y; Yoshiki R; Kawakami C; Fukamachi S; Sugita K; Nakamura M; Tokura Y Acta Derm Venereol; 2010 Sep; 90(5):521-2. PubMed ID: 20814632 [No Abstract] [Full Text] [Related]
31. [New effective dosage of valsartan. High dosage--effective against high blood pressure]. MMW Fortschr Med; 2007 Nov; 149(46):52-3. PubMed ID: 18069195 [No Abstract] [Full Text] [Related]
32. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548 [TBL] [Abstract][Full Text] [Related]
33. The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID). Yamazaki T; Kohro T; Chujo M; Ishigaki M; Hashimoto T Hypertens Res; 2013 Feb; 36(2):140-50. PubMed ID: 23096231 [TBL] [Abstract][Full Text] [Related]
35. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Viberti G; Wheeldon NM; Circulation; 2002 Aug; 106(6):672-8. PubMed ID: 12163426 [TBL] [Abstract][Full Text] [Related]
36. [Tolerance to valsartan in office practice in 3,197 hypertensive patients (the VALSE study)]. Ghannad E; Francillon A; Vaillant J; Bourdeix I; Gosse P Ann Cardiol Angeiol (Paris); 2000 Feb; 49(1):13-20. PubMed ID: 12555316 [TBL] [Abstract][Full Text] [Related]
37. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. Bork K; Dewald G Am J Med; 2004 May; 116(9):644-5. PubMed ID: 15093766 [No Abstract] [Full Text] [Related]
38. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157 [TBL] [Abstract][Full Text] [Related]